Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

This study has been completed.
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00588237
First received: December 22, 2007
Last updated: December 15, 2015
Last verified: December 2015
Results First Received: December 15, 2015  
Study Type: Interventional
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Ovarian Cancer
Primary PERITONEUM
Fallopian Tube Cancer
Intervention: Drug: Paclitaxel,Cisplatin, Bevacizumab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
All Patients Paclitaxel, Cisplatin, Bevacizumab

Participant Flow:   Overall Study
    All Patients
STARTED   42 
COMPLETED   38 
NOT COMPLETED   4 
Evaluable for toxicity only                3 
Patien not treated                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
All Patients Paclitaxel, Cisplatin, Bevacizumab

Baseline Measures
   All Patients 
Overall Participants Analyzed 
[Units: Participants]
 42 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   40 
>=65 years   2 
Gender 
[Units: Participants]
 
Female   42 
Male   0 


  Outcome Measures

1.  Primary:   Overall Objective Response   [ Time Frame: 2 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Jason Konner
Organization: Memorial Sloan Kettering Cancer Center
phone: 646-888-4219
e-mail: konnerj@mskcc.org



Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00588237     History of Changes
Other Study ID Numbers: 06-064
Study First Received: December 22, 2007
Results First Received: December 15, 2015
Last Updated: December 15, 2015
Health Authority: United States: Institutional Review Board